Synapse - Works

Results (2639)

PK and PD assessment of BET inhibitor pelabresib (CPI-0610) in patients with relapsed or refractory lymphoma: Findings from a phase 1 study

Meeting Abstract

Blum, K. A.; Supko, J. G.; Maris, M.; Flinn, I. W.; Goy, A. H.; Younes, A.; Bobba, S.; Senderowicz, A.; Efuni, S.; Rippley, R.; more...
Blood (2021)

Fulltext@MSK | Save

A multi-institutional retrospective analysis of T-cell lymphomas with central nervous system relapse

Meeting Abstract

Bhansali, R. S.; Ganesan, N.; Stuver, R. N.; Horwitz, S. M.; Wudhikarn, K.; Hwang, S. R.; Bennani, N.; Chavez, J. C.; Sokol, L.; Saeed, H.; more...
Blood (2021)

Fulltext@MSK | Save

Interim analysis of the randomized phase 1b/3 study evaluating the safety and efficacy of tazemetostat plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma

Meeting Abstract

Batlevi, C. L.; Park, S. I.; Nastoupil, L.; Phillips, T.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Pagel, J. M.; Leonard, J. P.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 1 study of CFT7455, a novel degrader of IKZF1/3, in multiple myeloma and non-Hodgkin lymphoma

Meeting Abstract

Berdeja, J.; Ailawadhi, S.; Horwitz, S. M.; Matous, J. V.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Richardson, P. G.; Richard, S.; Bhutani, M.; more...
Blood (2021)

Fulltext@MSK | Save

Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study

Meeting Abstract

Bartlett, N. L.; Giri, P.; Budde, L. E.; Schuster, S. J.; Assouline, S.; Matasar, M. J.; Yoon, S. S.; Canales, M.; Gutierrez, N. C.; Fay, K.; more...
Blood (2021)

Fulltext@MSK | Save

Selective STAT3 degraders dissect peripheral T-cell lymphomas vulnerabilities empowering personalized regimens

Meeting Abstract

Astone, G.; Cappelli, L. V.; Chiu, W.; Kayembe, C.; Wang, R.; Yang, B.; Sharma, K.; Dey, J.; Karnik, R.; Brambilla, L.; more...
Blood (2021)

Fulltext@MSK | Save

Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL)

Meeting Abstract

Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Wang, M.; Arnason, J. E.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A. R.; more...
Blood (2021)

Fulltext@MSK | Save

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a Single-arm extension

Meeting Abstract

Sehn, L. H.; Hess, G.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

ECHELON-2, (NCT01777152), 5-year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin plus CHP vs CHOP in patients with CD30-positive peripheral T-cell lyphoma

Meeting Abstract

Trümper, L.; O'Connor, O. A.; Pro, B.; Illidge, T.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Meeting Abstract

Dreyling, M.; Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save